<DOC>
	<DOC>NCT00850616</DOC>
	<brief_summary>A study to assess the general safety and tolerability of the administration of the 3-dose regimen of the MRKAd5+6 trigene vaccine</brief_summary>
	<brief_title>Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject has negative tests for HIV, Hepatitis B, and Hepatitis C within 60 days of injection Subject agrees to use an acceptable method of birth control through week 52 of the study Subject has been given immune globulin or blood products within 30 days of first dose of study vaccine Subject has been vaccinated with a live virus vaccine within 30 days or an inactivated vaccine within 5 days of first dose of study vaccine Subject has known or suspected impaired immune function Subject has participated in any other HIV vaccine trial Female subject is pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Preventive Vaccine</keyword>
</DOC>